Reference Number: 07-27
Inventors: Stephan H. Bossmann; Deryl L. Troyer; Matthew T. Basel
Background:
Serine proteases are markers for the ability of many cancers to grow and to form metastases. Several serine proteases are over-expressed by numerous cancer cell lines. Elevated expression levels of urokinase and several other components of the plasminogen activation system are found to be correlated with tumor malignancy.
This invention is comprised of a urokinase cleavage sequence, which is used as a linker between two fluorophores (quantum dots and/or organic or inorganic dyes). Depending on the nanoparticles used, optical (fluorescence), magnetic (MRI), and x-ray imaging of the tumor location and extension, together with quantitative determination of the urokinase activity, can be performed. This assay method is useful for the quantitative determination of any enzyme that can cleave a specific linker between two fluorphores.
Advantages:
Advantages of this IP over previous methods:
Applications
This innovative technology can be used to:
Patent Status
Kansas State University Research Foundation seeks to have discussions with companies that are interested in licensing and/or research collaborations.
Interested parties should contact:
National Institute for Strategic Technology Acquisition and
Commercialization (NISTAC)
2005 Research Park Circle Manhattan, KS 66502
Tel: 785-532-3900 Fax: 785-532-3909
E-Mail: nistac@ksu.edu